| 000 | 01676 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514235349.0 | ||
| 264 | 0 | _c20051115 | |
| 008 | 200511s 0 0 eng d | ||
| 022 | _a0269-2813 | ||
| 024 | 7 |
_a10.1111/j.1365-2036.2005.02547.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChen, L-T | |
| 245 | 0 | 0 |
_aalpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _cAug 2005 |
||
| 300 |
_a217-26 p. _bdigital |
||
| 500 | _aPublication Type: Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAngiogenesis Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xblood |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xblood |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver Neoplasms _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aThalidomide _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aalpha-Fetoproteins _xmetabolism |
| 700 | 1 | _aLiu, T-W | |
| 700 | 1 | _aChao, Y | |
| 700 | 1 | _aShiah, H-S | |
| 700 | 1 | _aChang, J-Y | |
| 700 | 1 | _aJuang, S-H | |
| 700 | 1 | _aChen, S-C | |
| 700 | 1 | _aChuang, T-R | |
| 700 | 1 | _aChin, Y-H | |
| 700 | 1 | _aWhang-Peng, J | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 22 _gno. 3 _gp. 217-26 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2036.2005.02547.x _zAvailable from publisher's website |
| 999 |
_c15729146 _d15729146 |
||